Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Biotech·Amani Therapeutics

Schizophrenia drug startup Amani Therapeutics sold $35M in stock, SEC filing shows

A Form D filed Oct. 1 shows the RTW-backed New York company sold $35 million of a planned $60 million equity offering to five investors. Amani has announced only one financing, a $25 million Series A in March.

Charted Staff2 min read
From an SEC Form D filed Oct. 1, 2026, an earlier Form D filed Dec. 10, 2025, and a company announcement published March 23, 2026
AstraZeneca's Discovery Centre, photographed in 2025.
AstraZeneca's Discovery Centre, photographed in 2025. File photo.Mr Ignavy / Wikimedia Commons (CC BY-SA 2.0)
Amount
$35M
Type
Private placement
Company
Amani Therapeutics
Sector
Biotech
Announced
Oct. 1, 2026

Amani Therapeutics has told the public about one financing: a $25 million Series A in March. Its filings with the Securities and Exchange Commission show more money than that.

The New York biotech, formed with backing from RTW Investments to develop a schizophrenia treatment, sold $35 million in equity in a new private offering, according to a Form D filed with the SEC on Oct. 1. The filing puts the total offering at about $60 million, leaving $25 million unsold, and lists Sept. 16 as the date of first sale.

Why it matters: Amani is developing a version of the antipsychotic clozapine meant to address the safety risk and monitoring burden that, the company says, limit the drug's use. The two Form Ds on file report about $66 million in equity sold, well above the $25 million the company has announced, though neither says who invested or on what terms.

A Form D is a short notice that companies file after selling securities in a private offering that is exempt from SEC registration. It reports how much was sold, not who bought or why. Amani's lists five investors, all accredited, no sales commissions or finder's fees, and an offering expected to last no more than a year.

No company announcement of the raise could be found. The news section of Amani's website lists only the March 23 Series A release.

What the filing shows, and what it doesn't

The Form D names RTW Holdings VI LLC as a promoter of the offering. It lists Alice Lee and Robert Swoboda as executive officers; Swoboda, who signed the filing, is chief operating officer. Lauren Cuje, Peter Fong and Connor Williams are listed as directors. Amani was incorporated in Delaware in 2025, lists its industry as "Other Health Care" and declined to disclose its revenue range.

The filing does not identify the investors beyond their number, name a series of stock or a lead investor, give a valuation, or say how the money will be spent.

Amani's only earlier Form D, filed in December 2025, reported a fully sold $31.1 million equity offering to two investors, with a first sale on Nov. 25, 2025. The March release described the Series A as $25 million, and the filings do not explain the gap between the two figures.

The program

Amani said in March that its lead program, AM-01, combines clozapine in a fixed dose with a Phase 3-ready new chemical entity to which it in-licensed worldwide rights from AstraZeneca. It did not name that compound.

The company says it is targeting clozapine's risk of severe neutropenia, a drop in infection-fighting white blood cells, and the blood monitoring that it says limits the drug's use. Carla Canuso, Amani's chief medical officer, said in the March release that the company's understanding of the mechanism, "supported by results from our preclinical models," led it to believe it had found a solution.

Swoboda previously was senior vice president of corporate and portfolio operations at Karuna Therapeutics, where the March release said he led the cross-functional program for Cobenfy. Canuso was head of neuropsychiatry at Johnson & Johnson, according to the release.

What to watch

Amani has not said when AM-01 will enter a Phase 3 trial or how it plans to use the new money. As of the filing, $25 million of the offering remained unsold.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Biotech

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.